TerminatedPHASE1, PHASE2NCT00699842

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Principal Investigator: Emmanuel Besa, MD
Thomas Jefferson University
Intervention: Lenalidomide(drug)
Enrollment: 8 enrolled
Eligibility: 18 years · All sexes
Timeline: 2008 – 2012

Study locations (2)

Associates in Hematology-Oncology, PC, Chester, Pennsylvania, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Collaborators

Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00699842 on ClinicalTrials.gov

Other trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies

See all trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality →

← Back to all trials